3 recruiting, 1 active not recruiting. 2 Phase 1, 2 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 1 | 2 | Recruiting 2 |
| Phase 2 | 2 | Active not recruiting 1, Recruiting 1 |
Follow Locally Advanced Merkel Cell Carcinoma: new trials by email Literature Review of Locally Advanced Merkel Cell Carcinoma trials Research Report on Locally Advanced Merkel Cell Carcinoma
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Studying Off Label Insurance Coverage for Patients With Cutaneous Cancers a "Filter" Observational Study Non-Interventional Study - Clinical Stage II Cutaneous Merkel Cell Carcinoma AJCC v8, Clinical Stage III Cutaneous Merkel Cell Carcinoma AJCC v8 | Recruiting | Ohio State University Comprehensive Cancer Center | 70 | 2026-02-04 | 2026-06-25 | |
| Evaluating BL-M14D1 in Subjects With Locally Advanced or Metastatic Small Cell Lung Cancer and Neuroendocrine Tumors BL-M14D1 - Small Cell Lung Cancer Metastatic or Locally Advanced, Neuroendocrine Cancer | Phase 1 | Recruiting | SystImmune Inc. | 120 | 2025-04-28 | 2026-10-30 |
| Testing the Combination of Two Anticancer Drugs M1774 (Tuvusertib) and Avelumab to Evaluate Their Safety and Effectiveness in Treating Merkel Cell Skin Cancer, MATRiX Trial Avelumab, Biopsy Procedure, Biospecimen Collection - Clinical Stage III Cutaneous Merkel Cell Carcinoma AJCC v8, Clinical Stage IV Cutaneous Merkel Cell Carcinoma AJCC v8 | Phase 2 | Active not recruiting | National Cancer Institute (NCI) | 50 | 2024-05-21 | 2026-07-31 |
| Personalized Neoantigen Peptide-Based Vaccine in Combination With Pembrolizumab for Treatment of Advanced Solid Tumors Cyclophosphamide, Neoantigen Peptide Vaccine, Pembrolizumab - Anatomic Stage III Breast Cancer AJCC v8, Anatomic Stage IIIA Breast Cancer AJCC v8 | Phase 1 / Phase 2 | Recruiting | Mayo Clinic | 138 | 2022-03-31 | 2026-08-20 |
Carcinoma, Merkel Cell (2) · Carcinoma, Hepatocellular (1) · Carcinoma, Lobular (1) · Carcinoma, Neuroendocrine (1) · Carcinoma, Non-Small-Cell Lung (1) · Carcinoma, Renal Cell (1) · Carcinoma, Transitional Cell (1) · Carcinosarcoma (1) · Endometrial Neoplasms (1) · Lung Neoplasms (1) · Melanoma (1) · Neoplasm Metastasis (1) · Squamous Cell Carcinoma of Head and Neck (1) · Triple Negative Breast Neoplasms (1) · Uterine Cervical Neoplasms (1)
Adenocarcinoma (3) · Carcinoma (3) · Neoplasms (3) · Neoplasms by Histologic Type (3) · Neoplasms, Germ Cell and Embryonal (3) · Neoplasms, Glandular and Epithelial (3) · Neoplasms, Nerve Tissue (3) · Neuroectodermal Tumors (3) · Neuroendocrine Tumors (3) · Carcinoma, Neuroendocrine (2) · DNA Virus Infections (2) · Infections (2) · Polyomavirus Infections (2) · Tumor Virus Infections (2) · Virus Diseases (2)
Biopsy (2) · Magnetic Resonance Spectroscopy (2) · Specimen Handling (2) · Colony-Stimulating Factors (1) · Cyclophosphamide (1) · Immunoglobulin G (1) · X-Rays (1) · avelumab (1) · pembrolizumab (1) · sargramostim (1)
Mayo Clinic (1) · National Cancer Institute (NCI) (1) · Ohio State University Comprehensive Cancer Center (1) · SystImmune Inc. (1)
United States (4) · Canada (1) · Georgia (1) · Ukraine (1)
Claire F Verschraegen, MD (1) · Junliang Cai (1) · Paul Nghiem (1) · Yanyan Lou, MD, PhD (1)
P30CA015704 (1)